Stockreport

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease [Yahoo! Finance]

Maze Therapeutics, Inc.  (MAZE) 
PDF Maze Therapeutics, Inc. Fri, February 7, 2025 at 2:00 PM GMT+1 5 min read In This Article MAZE Maze Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., Feb. 07, [Read more]